http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010111872-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aeee8d3f65d495ab7c77f7132d3b5da2 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
filingDate | 2008-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65b7ab7983613beaf2c19af39c162e75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3c359c8c157805153e106447e63f2fd |
publicationDate | 2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2010111872-A1 |
titleOfInvention | System and method for modulating and optimizing immunotherapy |
abstract | A method for modulating a subject's type of immune response to a cancer treatment. The method comprises the steps of: (a) obtaining a sample from subject; (b) assessing the sample to detect IgG antibodies or IgG isotypes in the sample; (c) if IgG antibodies or IgG isotypes are detected, then identifying and quantifying their expression; (d) comparing the quantified IgG antibodies or IgG isotypes with a control to determine the changes, and characterize the immune response. The changes in expression of IgG antibodies or IgG isotypes are indicative of the type of immune response to the cancer treatment. Steps (a) through (f) are repeated for each of a series of spaced-apart time points. The series of characterized immune responses are assessed to determine the subject's responsiveness to the cancer treatment. The cancer treatments are then modulated to affect desired changes in expression of IgG antibodies or IgG isotypes. |
priorityDate | 2008-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.